Abstract:e20525 Background: Lung cancer is the leading cause of cancer related deaths in China. Along with rapid development of new technologies, the modes of surgeries are experiencing changes. The purposes of the study are to investigate the status quo of surgical operations in Chinese patients. Methods: The study data on the patients with lung cancer (≥ 18 years) who received surgeries in the top 10 study sites from 2014 to 2017 were collected from the collaborative prospective LinkDoc database. The overall survial (OS) was measured based on the method of propensity score matching. Results: A total of 21,772 patients (ratio of male/female: 1.3, 71.7% adenocarcinoma) were recruited. Of all, 59.8% of subjects were non-smokers. The majority of patients (71.4%) were performed with minimally invasive thoracic surgeries (MITS) and most subjects with surgeries were early-stage patients (Ia:47.2%;Ib:14.9%). The percentages of patients with post-operative complications and patients with 30-day mortality rate were 6.5% and 0.54%, respectively. The 1-, 2-, and 3-year OS rates (94.9%, 87.1%, 78.9%) of the patients with MITS were significantly higher than those of the patients (88.1%, 76.2%, 66.5%) with thoracotomy (p < 0.01) (Table 1). Conclusions: In the Chinese patients with surgeries, the proportions of females, non-smokers, early-stage patients, and patients with adenocarcinoma are increasing. The minimally invasive thoracic surgeries have been well developed and performed without compromising perioperative morbidity and mortality. The patients with MITS were observed with better survival benefits compared to those patients with thoractomy within the short follow-up observation period. Clinical trial information: NCT03421093.Table 1 Clinical characteristics of patients with surgeries Parameters Clinical data Gender (%) Male 56.5% Female 43.5% Age (years) 59.3±9.8 Smoking history (%) Non-smoking 59.8% Smoking 20.0% Ever smoked 20.2% Pathological type (%) Adenocarcinoma 71.7% TNM stage (%) Ia 47.2% Ib 14.9% Modes of surgeries (%) Thoracotomy 24.8% VATS 70.0% VATS (Conversion) 3.7% RATS 1.4% Surgical operations Surgical duration (minutes) 152.8±69 Lymph nodes dissection (number) 13.3±9.77 Postoperative stay (days) 9.1±6.16 Perioperative morbidity (%) 6.5% 30-day mortality (%) 0.54%

On Progress in Surgical Treatment of Lung Cancer

[Advances in Surgical Treatment of Early Stage Non-small Cell Lung Cancer].

Surgical Treatments of Chinese Patients with Lung Malignant Tumors.

New progress in immunotherapy of lung cancer

Current Status of Clinical Trials about Thoracic Surgery in Lung Cancer

Advanced Surgical Technologies for Lung Cancer Treatment: Current Status and Perspectives

Prevention and management of lung cancer in China.

Evolution of Method and Idea of Surgical Treatment on Lung Cancer

A Review of Advances in the Surgical Treatment of Coronary Heart Disease and Lung Cancer.

Important clinical research progress in lung cancer in 2022

Lung Cancer Screening in China: Early-Stage Lung Cancer and Minimally Invasive Surgery 3.0

Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Lung Cancer Molecular Epidemiology in China: Recent Trends.

[Minimally Invasive Therapies for Early Stage Non-small Cell Lung Cancer].

[Advances and Improvements in the Diagnoses and Treatments of Lung Cancer].

The Clinical Analysis of Surgical Treatment for 362 Cases Lung Cancer Patients

Research on surgical treatment for non-small cell lung cancer from 2009 to 2018: a bibliometric analysis

Advancements in radiotherapy for lung cancer in China

The Evolution of the Treatment of Non-small Cell Lung Cancer: A Shift in Surgical Paradigm to A More Individualized Approach

Ten-year trends of the clinicopathological characteristics, surgical treatments and survival outcomes of operable lung cancer patients in monocenter: a retrospective cohort study